삼출성 연령관련황반변성에서 유리체강내 베바시주맙 주입술의 해부학적 비반응군 조사

• 영문명: Anatomical Non-Responder to Intravitreal Bevacizumab for Neovascular Age-Related Macular Degeneration
• 발행기관: 대한안과학회
• 저자명: 조성우 배정훈 송수정,Sung Woo Cho, MD, Jeong Hun Bae, MD, Su Jeong Song, MD
• 간행물 정보: 『대한안과학회지』Ophthalmological Society,volume51,number11, 1464~1470쪽, 전체 7쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2010.11.15

영문 초록

Purpose: To analyze the characteristics of anatomical non-response to intravitreal bevacizumab (IVB) in patients with neovascular age-related macular degeneration (AMD). Methods: Neovascular AMD patients who were treated with IVB were studied. A non-responder was defined as a patient whose eyes had no change in choroidal neovascularization (CNV) lesion size or fluorescein leakage and no change in foveal thickness (FT) after at least two administrations of IVB. Demographic findings and efficacy outcomes were compared between responders and non-responders based on patient gender, age, visual acuity (VA), FT, CNV lesion type, CNV lesion size, presence of serous retinal detachment (SRD), presence of pigment epithelial detachment (PED), PED size, and presence of sub-macular hemorrhage (SMH). Results: Five patients (six eyes; 13.6%) were identified as non-responders to treatment with IVB. The mean age of the non-responder group (75.17 ± 3.66 yers) was greater (p = 0.237) than that of the responder group (71.89 ± 8.06 years), and the proportion of occult CNV (85.7% versus 55.3%, p = 0.375) was higher in the non-responder group, although there was no significant difference compared with that of the responder group. The PED size of the non-responder group (4.42 ± 1.56 mm2) was significantly larger than that of the responder group (1.51 ± 2.33 mm2, p = 0.001). Conclusions: The authors report a group of patients in AMD with poor treatment response to IVB. The PED size of the non-responder group was confirmed to be significantly larger than that of the responder group. J Korean Ophthalmol Soc 2010;51(11):1464-1470

키워드

Age-related macular degeneration (AMD), Avastin, Bevacizumab, Non-responder